1. EMBO Mol Med. 2017 Feb;9(2):238-250. doi: 10.15252/emmm.201606646.

The RAS-related GTPase RHOB confers resistance to EGFR-tyrosine kinase 
inhibitors in non-small-cell lung cancer via an AKT-dependent mechanism.

Calvayrac O(1)(2), Mazières J(3)(2)(4), Figarol S(1), Marty-Detraves C(1), 
Raymond-Letron I(5), Bousquet E(4), Farella M(1)(6), Clermont-Taranchon E(7), 
Milia J(2)(4), Rouquette I(7), Guibert N(1)(4), Lusque A(8), Cadranel J(9), 
Mathiot N(9), Savina A(10), Pradines A(1)(6), Favre G(3)(2)(6).

Author information:
(1)Inserm, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, 
Toulouse, France.
(2)Université Paul Sabatier, Toulouse, France.
(3)Inserm, Centre de Recherche en Cancérologie de Toulouse, CRCT UMR-1037, 
Toulouse, France mazieres.j@chu-toulouse.fr favre.gilles@iuct-oncopole.fr.
(4)CHU Toulouse, IUCT-Rangueil-Larrey, Service de Pneumologie, Toulouse, France.
(5)Laboratoire d'Histopathologie, UPS-INP-ENVT, UMS006, Université de Toulouse, 
Toulouse, France.
(6)Laboratoire de Biologie Médicale Oncologique, Institut Claudius Regaud, 
IUCT-Oncopole, Toulouse, France.
(7)Departement d'Anatomo-Cytopathologie, CHU de Toulouse, IUCT-Oncopole, 
Toulouse, France.
(8)Institut Claudius Regaud, IUCT-Oncopole, Bureau des Essais Cliniques, Cellule 
Biostatistiques, Toulouse, France.
(9)Sorbonne Universités UPMC Univ. Paris 06 GRC n°04 Theranoscan, Paris AP-HP, 
Hôpital Tenon, Service de Pneumologie, Paris, France.
(10)Institut Roche, Roche SAS, Boulogne-Billancourt, France.

Although lung cancer patients harboring EGFR mutations benefit from treatment 
with EGFR-tyrosine kinase inhibitors (EGFR-TKI), most of them rapidly relapse. 
RHOB GTPase is a critical player in both lung carcinogenesis and the EGFR 
signaling pathway; therefore, we hypothesized that it could play a role in the 
response to EGFR-TKI In a series of samples from EGFR-mutated patients, we found 
that low RHOB expression correlated with a good response to EGFR-TKI treatment 
while a poor response correlated with high RHOB expression (15.3 versus 
5.6 months of progression-free survival). Moreover, a better response to 
EGFR-TKI was associated with low RHOB levels in a panel of lung tumor cell lines 
and in a lung-specific tetracycline-inducible EGFRL858R transgenic mouse model. 
High RHOB expression was also found to prevent erlotinib-induced AKT inhibition 
in vitro and in vivo Furthermore, a combination of the new-generation AKT 
inhibitor G594 with erlotinib induced tumor cell death in vitro and tumor 
regression in vivo in RHOB-positive cells. Our results support a role for 
RHOB/AKT signaling in the resistance to EGFR-TKI and propose RHOB as a potential 
predictor of patient response to EGFR-TKI treatment.

© 2016 The Authors. Published under the terms of the CC BY 4.0 license.

DOI: 10.15252/emmm.201606646
PMCID: PMC5286377
PMID: 28003335 [Indexed for MEDLINE]